Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to examine the short-term consequences of trauma and to determine the effectiveness of the drug sertraline in preventing and treating post-traumatic stress disorder (PTSD) and acute stress disorder (ASD) symptoms.

ASD and PTSD are common consequences of exposure to traumatic events. Despite growing evidence of neurobiological dysfunction in ASD and PTSD, the origin of these disorders is still unknown. This study will attempt to identify psychophysiological markers of ASD and find an effective treatment for its symptoms.

Victims of serious motor vehicle collisions will be evaluated with clinical assessments and standardized questionnaires within 2 weeks after the accident. Symptoms of exaggerated startle, emotional reactivity to trauma-related and trauma-unrelated cues, and cerebellum functioning will be evaluated. Participants will be randomized to receive either sertraline or placebo (an inactive sugar pill) for 8 weeks. Psychometric testing and psychological evaluations will be conducted 4, 10, and 14 weeks after the accident and after a 2-week taper of the study medication.


Clinical Trial Description

Acute stress disorder (ASD) and posttraumatic stress disorder (PTSD) are common consequences of exposure to traumatic events. Despite growing evidence of neurobiological dysfunction in ASD and PTSD, the pathogenesis of these disorders is still unknown. Drs. Osuch and Ursano (Uniformed Services University of the Health Sciences) have received support to conduct a 14-week study that will investigate the efficacy of the serotonergic medication sertraline (Zoloft) in the treatment and prevention of posttraumatic psychiatric sequelae in ASD victims. The present project is an amendment to Drs. Osuch and Ursano's study. It will attempt to identify early psychological and neurobiological abnormalities in ASD. More specifically, the present project will examine to what extent sensitization and conditioning processes, as well as emotional dysregulation, contribute to ASD. We also propose to investigate the potential association between cerebellum dysfunction and peritraumatic dissociations. To accomplish this goal, a series of three experiments will be implemented to investigate: 1) the symptom of exaggerated startle; 2) emotional reactivity to trauma-related and trauma-unrelated cues; and 3) cerebellum functioning using eyeblink conditioning. This study will inform on the short-term consequences of trauma, will help identify potential psychophysiological markers of ASD that emerge following trauma, and will examine the effects of an SSRI on preventing trauma-related neurobiological deficits.

We specifically propose to:

1. Characterize psychophysiological responses in ASD victims shortly after trauma;

2. Assess the effect of sertraline treatment on these psychophysiological responses.

To accomplish aim 1, non-treated ASD victims will be compared to two control groups, a non-ASD trauma group and a non-trauma healthy group. The two control groups will be used to disentangle the effect of trauma from the effect of acute stress disorder. To accomplish aim 2, the ASD sertraline group will be compared to the ASD placebo group following treatment.

Forty victims of serious motor vehicle collision (MVC) with ASD will be recruited from a community hospital emergency room and evaluated with clinical assessments, and standardized questionnaires within 2 weeks after the MVC. The subjects will then be randomized to either sertraline or placebo for 8 weeks duration. Psychometric testing and psychological evaluations will be conducted at 4, 10 weeks post-MVC, and after a 2-week taper of the medication and 2 more weeks (14 weeks post-MVC).

We hypothesize that ASD patients will show:

An enhancement or sensitization of baseline startle;

An increase in autonomic arousal and in startle amplitude to trauma-related cues;

A delayed eyeblink conditioning;

Normalization of these deficits after sertraline treatment.

This preliminary study is expected to lay the groundwork for a larger study of the early impact of traumatic events on psychophysiological and psychological processes. In the long-term, we expect to 1) better characterize the onset of symptoms and their evolution over time following trauma, 2) identify psychophysiological markers for PTSD, 3) identify ASD victims at-risk for PTSD, and 4) improve our ability to prevent the development of chronic psychopathology following trauma. ;


Study Design

Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00050804
Study type Interventional
Source National Institutes of Health Clinical Center (CC)
Contact
Status Completed
Phase Phase 4
Start date December 2002
Completion date February 2004

See also
  Status Clinical Trial Phase
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Withdrawn NCT00641173 - Early Intervention for Post Traumatic Stress Disorder (PTSD) N/A
Completed NCT00564317 - KIDNET vs Meditation/Relaxation - a Dissemination Randomized Controlled Trial for the Treatment of Traumatized Children After War in Sri Lanka Phase 3
Recruiting NCT02512445 - Trauma Informed Guilt Reduction Therapy N/A
Completed NCT00100490 - Immune and Endocrine Function in Post-Traumatic Stress Disorder N/A
Terminated NCT03605342 - Optimal Treatment of Veterans With PTSD and Comorbid OUD Phase 2
Terminated NCT02824445 - To Evaluate the Efficacy of EEG-guided Magnetic Resonant Therapy in War Veterans With Posttraumatic Stress Disorder N/A
Recruiting NCT03152175 - Posttraumatic Stress Disorders in Police, Correctional Service Officers, and 911 Operators Phase 2
Completed NCT02080351 - A Simple Cognitive Task to Reduce the Build-Up of Flashbacks After a Road Traffic Accident N/A
Completed NCT00974402 - Psychotherapy Treatment of Deployment-Related PTSD in Primary Care Settings N/A
Recruiting NCT00134446 - Transcranial Magnetic Stimulation for Post-Traumatic Stress Disorder Phase 4
Not yet recruiting NCT02384369 - Trial of Oral SNC-102 in Subjects With Combat-Related Posttraumatic Stress Disorder Phase 2
Completed NCT00120250 - Eszopiclone for Sleep Disturbance and Nightmares in Post-Traumatic Stress Disorder Phase 4
Completed NCT00039715 - Effects of Hydrocortisone in Patients With Post-Traumatic Stress Disorder N/A
Recruiting NCT04368689 - The Feasibility and Examination of the Effects of Floatation-based REST on a Community Sample With PTSD N/A
Completed NCT01060553 - Pilot of Acupuncture to Improve Quality of Life in Veterans With TBI and PTSD N/A
Completed NCT00227357 - The CORE Buprenorphine Project - An HIV Primary Care Program Demonstration N/A
Completed NCT02927288 - Identifying Biomarkers That Distinguish PTSD and mTBI Using Advanced Magnetic Resonance Spectroscopy N/A
Completed NCT01278316 - Rural Veterans With Post-traumatic Stress Disorder (PTSD) And Comorbid Mild Traumatic Brain Injury (TBI): A Feasibility Study N/A
Completed NCT00778960 - Mechanistic Pathways of Mindfulness Meditation in Post-traumatic Stress Disorder. N/A